ISM 6331
Alternative Names: ISM-6331; TEAD transcription factors targeting therapeutic - InSilico MedicineLatest Information Update: 27 Aug 2024
At a glance
- Originator InSilico Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Aug 2024 InSilico Medicine Hong Kong Limited plans a phase I trial for Soild tumours (Late-stage disease, Metastatic disease) and Mesothelioma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) (PO) in October 2024 (NCT06566079)
- 08 Jun 2023 Preclinical trials in Solid tumours in USA (PO) (InSilico Medicine Pipeline, August 2023)
- 08 Jun 2023 Pharmacodynamics data from a preclinical study in Solid tumours released by Insilico Medicine